# Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

> **NCT07750574** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chengdu Zenitar Biomedical Technology Co., Ltd** · enrollment: 105 (estimated)

## Conditions studied

- Myelofibrosis
- Myelofibrosis Due to and Following Polycythemia Vera
- Myelofibrosis Transformation in Essential Thrombocythemia
- Myelofibrosis With High Molecular Risk Mutations
- Myelofibrosis With Myeloid Metaplasia
- Myelofibrosis, Post ET
- Myelofibrosis, Post PV
- Myelofibrosis, Primary
- Myelofibrosis; Anemia
- Myelofibrosis，MF
- Myelofibrosis (PMF)
- Myeloid Metaplasia

## Interventions

- **DRUG:** Flonoltinib Maleate orally
- **DRUG:** Flonoltinib Maleate orally
- **DRUG:** Flonoltinib Maleate orally

## Key facts

- **NCT ID:** NCT07750574
- **Lead sponsor:** Chengdu Zenitar Biomedical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07750574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07750574, "Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07750574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*